Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 1, p. s2, 2021. DOI: 10.25251/skin.5.supp.2. Disponível em: https://skin.dermsquared.com/skin/article/view/1154. Acesso em: 19 apr. 2025.